| Today's Edition
Wednesday May 11th, 2016
Stay ahead of the pack with "The QualityStocks Daily", our summary formatted newsletter
containing stock tips from hundreds of online investment newsletters.
Daily.QualityStocks.net
Cocrystal Pharma, Inc. (COCP)
Wall Street Resources, Microcapmillionaires, and PennyStocks Forever reported earlier on Cocrystal Pharma, Inc. (COCP), and we report on the Company today, here at the QualityStocks Daily Newsletter.
Cocrystal Pharma, Inc. is a biotechnology company developing novel antiviral therapeutics for human diseases. The Company utilizes innovative technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. The design of these technologies, including its nucleoside chemistry expertise and market-focused approach to drug discovery, are to efficiently deliver small molecule therapeutics that are safe, effective, as well as convenient to administer. Cocrystal Pharma has offices in Tucker, Georgia and Bothell, Washington.
The Company has earlier received strategic investments from Teva Pharmaceuticals, OPKO Health (OPK), Brace Pharmaceutical, LLC, and The Frost Group. Cocrystal Pharma has identified promising, preclinical stage antiviral compounds for unmet medical needs including hepatitis, influenza and norovirus infections.
Cocrystal Pharma’s proprietary technologies revolve around a structure-based drug discovery strategy teamed up with comprehensive nucleoside experience. Utilizing techniques called protein cocrystallization and X-ray crystallography, the Company quickly identifies novel binding sites, identifies critical inhibitor-protein interactions, and optimizes the structure of the inhibitor in a highly rapid iterative fashion.
Cocrystal Pharma is developing a series of compounds, which are potent non-nucleoside and nucleoside inhibitors of hepatitis C NS5B RNA dependent RNA polymerase, a replication enzyme that is critical to viral replication and is highly conserved between all hepatitis C genotypes. Consequently, inhibitors of this enzyme are likely to have multi- or pan-genotypic activity.
In addition, the Company is developing compounds that inhibit hepatitis C helicase and NS5A, two enzymes essential for viral replication. It has also identified a picomolar inhibitor of NS5A, another essential viral replication protein. Cocrystal’s compounds that target NS5B hepatitis C polymerase, NS5A and NS3 helicase will undergo development as a combination treatment.
Cocrystal Pharma’s award-winning team includes three industry leaders. These are Dr. Roger Kornberg (Founder and Chief Scientist), Mr. Raymond F. Schinazi (Founder and Chairman of its Board of Directors) and Mr. Phillip Frost (member of its Board of Directors).
This past February, Cocrystal Pharma announced it signed an agreement with Duke University and Emory University to license different patents and knowledge to use CRISPR/Cas9 technologies for developing a possible cure for hepatitis B virus (HBV) and human papilloma virus (HPV). The license agreement permits Cocrystal Pharma to develop and potentially commercialize a cure for HBV and HPV using the underlying patents and technologies developed by the universities.
In April, Cocrystal Pharma announced that it initiated a Phase Ia/Ib clinical study of CC-31244, a pan-genotypic, potent NS5B non-nucleoside inhibitor (NNI), for the treatment of chronic hepatitis C virus (HCV) infection. The study is presently enrolling subjects. It has dosed the first subject with no serious adverse events reported.
Cocrystal Pharma, Inc. (COCP), closed Wednesday's trading session at $0.6155, down 0.73%, on 81,041 volume with 36 trades. The average volume for the last 60 days is 153,981 and the stock's 52-week low/high is $0.455/$1.47.
|
